vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Opera Ltd (OPRA). Click either name above to swap in a different company.
Opera Ltd is the larger business by last-quarter revenue ($142.7M vs $83.5M, roughly 1.7× BillionToOne, Inc.). Opera Ltd runs the higher net margin — 12.8% vs 6.8%, a 6.0% gap on every dollar of revenue.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Opera is a multinational technology corporation headquartered in Oslo, Norway, with additional offices in Europe, China, and Africa. Opera offers a range of products and services that include PC and mobile web browsers, GameMaker and gaming portals, the Opera News content recommendation products, the Opera Ads platform, and a number of Web3 and e-commerce products and services. The company's total user base is 296 million monthly active users.
BLLN vs OPRA — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $142.7M |
| Net Profit | $5.7M | $18.3M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | 14.8% |
| Net Margin | 6.8% | 12.8% |
| Revenue YoY | 117.4% | — |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $83.5M | — | ||
| Q1 25 | — | $142.7M | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | — | $211.6M |
| Q3 25 | $5.7M | — | ||
| Q1 25 | — | $18.3M | ||
| Q3 24 | $-14.9M | — | ||
| Q2 24 | — | $34.1M |
| Q3 25 | 69.9% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — |
| Q3 25 | 11.5% | — | ||
| Q1 25 | — | 14.8% | ||
| Q3 24 | -32.9% | — | ||
| Q2 24 | — | 19.6% |
| Q3 25 | 6.8% | — | ||
| Q1 25 | — | 12.8% | ||
| Q3 24 | -38.8% | — | ||
| Q2 24 | — | 16.1% |
| Q3 25 | $0.10 | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $-1.47 | — | ||
| Q2 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | — |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | — |
| Total Assets | $327.5M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $195.2M | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | $55.0M | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | $-239.5M | — | ||
| Q1 25 | — | — | ||
| Q3 24 | $-242.9M | — | ||
| Q2 24 | — | — |
| Q3 25 | $327.5M | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $13.8M | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | $6.5M | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | 7.7% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | 8.8% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | 2.42× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
OPRA
Segment breakdown not available.
